argenx SE reported third quarter 2026 financial results showing global product net sales of $1.7 billion, a 54% increase from the prior year and 13% growth quarter-over-quarter. Operating profit reached $486 million, driven by strong VYVGART performance in generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy. The company also announced positive Phase 3 ALKIVIA results for VYVGART Hytrulo in immune-mediated necrotizing myopathy and dermatomyositis, with a supplemental biologics license application on track for submission by year-end. Additionally, argenx advanced FB102 to Phase 3 in celiac disease based on positive Phase 2 data. Full-year combined R&D and SG&A expenses are now expected to be approximately $4 billion, including acquisition-related costs from the Forte Biosciences Inc. transaction. The company operates as an immunology innovation firm focused on developing treatments for autoimmune diseases.
